FORTUNE: The faulty forecasts of pharma firm investors: Misguided cynics miss the promising prognosis for drugmakers Pfizer and Merck | Yale School of Management

Chief Executive Leadership Institute Navigation Menu

CELI Home

About
- About About
- Directors Directors
- Legion of Leadership Legion of Leadership
- Maverick in Leadership Recipients Maverick in Leadership Recipients
- Legend in Leadership Recipients
- Lifetime of Leadership Recipients Lifetime of Leadership Recipients
Programs
- Programs Programs
- CEO Summit CEO Summit
- Yale Mayors College Yale Mayors College
- CEO Caucus CEO Caucus
- Yale Higher Education Leadership Summit Yale Higher Education Leadership Summit
- CEO College CEO College
Media
- Media
- Russia
- Middle East
Events
Contact
Search

Jeffrey Sonnenfeld discusses a prolonged stretch of share underperformance for both Pfizer and Merck even with paradoxically good revenues in FORTUNE

Related Stories

Glenn Fogel, President and CEO of Booking Holdings

Glenn Fogel, CEO of Booking Holdings, to Receive the Yale Legend in Leadership Award

Shoes

THE NEW YORK TIMES: Memo to the Business Elite: It's Time to Stand Up

Russian President Vladimir Putin speaks during his annual call-in-show and press conference at the Gostiny Dvor Hall in Moscow, Dec. 19, 2024

TIME: What CEOs Know about Putin that Stumps Donald Trump